We Need More Proof That Prenatal Gene Screens Are Beneficial
By The Editors,
Scientific American
| 02. 01. 2016
Untitled Document
Expecting a baby often provokes mixed emotions—wonder and amazement but also concern. Will the child be healthy? Happy? Find his or her spot in the world? Several prenatal blood tests are now available that attempt to ease some of the anxiety—at least about health. By analyzing trace amounts of fetal DNA in a pregnant woman's bloodstream, these tests (which go by such names as Harmony, MaterniT21 PLUS and verifi) can identify various genetic anomalies up to six months before birth. Whether or not parents to be take advantage of these laboratory measures is, of course, up to them. But results from screening tests can be misleading, and industry and federal regulators are not doing enough to ensure that people get all the information they need.
At present, the tests detect major abnormalities—such as three copies of the 21st, 18th or 13th chromosome, which lead, respectively, to Down, Edwards and Patau syndrome. These measures are a definite safety improvement over earlier procedures to check the genes of the unborn. Previously such chromosomal abnormalities could be detected prenatally only by...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...